The main indicators for determining the improvement of chronic granulocytic leukemia include bone marrow image, blood routine and changes in indicators such as tiny residual lesions. 1. The therapeutic effect of leukemia is mainly assessed by CR (complete remission), i.e., disappearance of signs and symptoms of leukemia, absence of primitive cells in peripheral blood, absence of extramedullary leukemia, restoration of hematopoiesis in the three lineages of the bone marrow, with primitive cells <5%, peripheral blood neutrophils >1.0×10⁹/L, and platelets ≥100×10 ⁹/L. Ideal CR is the disappearance of abnormal immunologic, cytogenetic, and molecular biology markers at the time of initial diagnosis. 2. When the disease obtains CR, the leukemia cells in the body drop from 10¹⁰~10¹² at the onset of the disease to 10⁸~10⁹, and these residual leukemia cells are called tiny residual foci (MRD), the MRD level predicts relapse, and must be monitored regularly, and the patients with consistently negative MRD are expected to obtain long-term disease-free survival Patients with consistently negative MRD are expected to have long-term disease-free survival, and clinical cure is achieved after more than 10 years of long-term disease-free survival. Leukemia is a relatively common malignant tumor. Once it occurs, patients should go to the hospital in a timely manner and be diagnosed and treated under the guidance of a professional doctor.